Zacks Research lowered shares of Journey Medical (NASDAQ:DERM – Free Report) from a hold rating to a strong sell rating in a report released on Thursday,Zacks reports.
A number of other analysts also recently issued reports on the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Journey Medical in a research report on Thursday, October 15th. B. Riley Financial reissued a “buy” rating and set a $13.00 price target (down from $15.00) on shares of Journey Medical in a research report on Friday. Wall Street Zen cut Journey Medical from a “buy” rating to a “hold” rating in a research report on Saturday, October 17th. Finally, HC Wainwright restated a “buy” rating and issued a $13.00 price target on shares of Journey Medical in a research note on Monday, October 26th. Two research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $13.00.
View Our Latest Stock Analysis on Journey Medical
Journey Medical Stock Down 1.4%
Journey Medical stock traded down $0.06 during mid-day trading on Thursday, reaching $4.33. The company’s stock had a trading volume of 387,161 shares, compared to its average volume of 185,290. The company has a market capitalization of $122.19 million, a price-to-earnings ratio of -24.05 and a beta of 1.14. Journey Medical has a 12 month low of $4.00 and a 12 month high of $9.56. The business’s 50 day simple moving average is $5.89 and its 200 day simple moving average is $6.47. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.41 and a current ratio of 1.59.
Journey Medical (NASDAQ:DERM – Get Free Report) last issued its quarterly earnings results on Thursday, November 12th. The company reported ($0.05) EPS for the quarter, missing the consensus estimate of ($0.02) by ($0.03). Journey Medical had a negative return on equity of 16.15% and a negative net margin of 7.34%. The business had revenue of $18.97 million for the quarter, compared to the consensus estimate of $20.32 million. As a group, research analysts anticipate that Journey Medical will post -0.13 earnings per share for the current year.
Hedge Funds Weigh In On Journey Medical
Several institutional investors and hedge funds have recently modified their holdings of the stock. Wasatch Advisors LP boosted its holdings in shares of Journey Medical by 34.0% during the 2nd quarter. Wasatch Advisors LP now owns 2,858,930 shares of the company’s stock worth $20,241,000 after buying an additional 725,560 shares during the period. Punch & Associates Investment Management Inc. acquired a new position in Journey Medical in the 2nd quarter valued at about $3,795,000. Pale Fire Capital SE raised its holdings in Journey Medical by 9.7% in the 2nd quarter. Pale Fire Capital SE now owns 528,584 shares of the company’s stock valued at $3,742,000 after acquiring an additional 46,597 shares during the period. First Eagle Investment Management LLC bought a new position in Journey Medical in the 3rd quarter valued at about $3,305,000. Finally, Marshall Wace LLP raised its holdings in Journey Medical by 38.9% in the 3rd quarter. Marshall Wace LLP now owns 194,311 shares of the company’s stock valued at $1,329,000 after acquiring an additional 54,468 shares during the period. 7.25% of the stock is currently owned by institutional investors and hedge funds.
Recent Journey Medical Headlines
These are some of the DERM headlines that stood out recently:
- Positive Sentiment: Journey Medical’s third-quarter loss narrowed and revenue increased, and a report said shares gained in after-hours trading following the results. Article
- Neutral Sentiment: B. Riley reaffirmed its “Buy” rating but cut its price target to $13 from $15. The lower target is a cautionary change, though it remains well above the $4.48 reference price cited in the report. Article
- Negative Sentiment: Quarterly adjusted loss was $0.05 per share, worse than the $0.02 loss analysts expected. Revenue of $18.97 million also missed the $20.32 million consensus, which could weigh on sentiment despite the year-over-year improvement. Earnings report
About Journey Medical
Journey Medical Corporation is a commercial-stage pharmaceutical company focused on developing and marketing prescription treatments for dermatological conditions. Founded in 2014 and based in Scottsdale, Arizona, the company primarily serves the U.S. market. Its portfolio includes treatments for conditions such as acne, rosacea, excessive underarm sweating and fungal skin infections. Products include Amzeeq and Zilxi, topical minocycline therapies; Qbrexza, a topical treatment for primary axillary hyperhidrosis; and the oral rosacea treatment Emrosi.
Further Reading
- Five stocks we like better than Journey Medical
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Journey Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Journey Medical and related companies with MarketBeat.com's FREE daily email newsletter.
